SEC Form 4 · accession 0001451612-26-000010

Kymera Therapeutics, Inc. · KYMR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Bruce Booth

Director

Period of report

Jun 17, 2026

Accepted (ET)

Jun 22, 2026 · 9:01 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001815442

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jun 17, 2026	M	11,741	$20.00	A	11,741	D
Common Stock^F2	Jun 17, 2026	S	11,741	$89.98	D	0	D
Common Stock^F4,F5	Jun 17, 2026	S	92,169	$90.38	D	3,807,660	I	See footnote
Common Stock^F4,F6	Jun 17, 2026	S	12,902	$90.38	D	662,042	I	See footnote
Common Stock^F7,F5	Jun 18, 2026	S	62,897	$90.48	D	3,744,763	I	See footnote
Common Stock^F8,F5	Jun 18, 2026	S	32,359	$91.85	D	3,712,404	I	See footnote
Common Stock^F9,F5	Jun 18, 2026	S	5,672	$92.16	D	3,706,732	I	See footnote
Common Stock^F7,F6	Jun 18, 2026	S	8,809	$90.48	D	653,233	I	See footnote
Common Stock^F8,F6	Jun 18, 2026	S	4,526	$91.85	D	648,707	I	See footnote
Common Stock^F9,F6	Jun 18, 2026	S	793	$92.16	D	647,914	I	See footnote
Common Stock^F10,F5	Jun 22, 2026	S	14,921	$92.14	D	3,691,811	I	See footnote
Common Stock^F11,F5	Jun 22, 2026	S	2,035	$94.48	D	3,689,776	I	See footnote
Common Stock^F12,F5	Jun 22, 2026	S	11,783	$95.12	D	3,677,993	I	See footnote
Common Stock^F13,F5	Jun 22, 2026	S	20,903	$96.24	D	3,657,090	I	See footnote
Common Stock^F14,F5	Jun 22, 2026	S	16,084	$97.68	D	3,641,006	I	See footnote
Common Stock^F15,F5	Jun 22, 2026	S	25,976	$98.58	D	3,615,030	I	See footnote
Common Stock^F16,F5	Jun 22, 2026	S	52,442	$99.57	D	3,562,588	I	See footnote
Common Stock^F17,F5	Jun 22, 2026	S	56,348	$100.17	D	3,506,240	I	See footnote
Common Stock^F18,F5	Jun 22, 2026	S	6,597	$101.61	D	3,499,643	I	See footnote
Common Stock^F19,F5	Jun 22, 2026	S	8,990	$102.48	D	3,490,653	I	See footnote
Common Stock^F10,F6	Jun 22, 2026	S	2,179	$92.14	D	645,735	I	See footnote
Common Stock^F11,F6	Jun 22, 2026	S	286	$94.48	D	645,449	I	See footnote
Common Stock^F12,F6	Jun 22, 2026	S	1,648	$95.12	D	643,801	I	See footnote
Common Stock^F13,F6	Jun 22, 2026	S	2,919	$96.24	D	640,882	I	See footnote
Common Stock^F14,F6	Jun 22, 2026	S	2,247	$97.68	D	638,635	I	See footnote
Common Stock^F15,F6	Jun 22, 2026	S	3,603	$98.58	D	635,032	I	See footnote
Common Stock^F16,F6	Jun 22, 2026	S	7,319	$99.57	D	627,713	I	See footnote
Common Stock^F17,F6	Jun 22, 2026	S	7,879	$100.17	D	619,834	I	See footnote
Common Stock^F18,F6	Jun 22, 2026	S	918	$101.61	D	618,916	I	See footnote
Common Stock^F19,F6	Jun 22, 2026	S	1,253	$102.48	D	617,663	I	See footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F20	$20.00	Jun 17, 2026	M	11,741	D	—	Aug 19, 2030	Common Stock	11,741	28,127	D

Explanation of responses

F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.11 to $92.50 inclusive.
F11The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.93 to $94.91 inclusive.
F12The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.99 to $95.76 inclusive.
F13The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.00 to $96.959 inclusive.
F14The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.0018 to $97.99 inclusive.
F15The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.00 to $98.9997 inclusive.
F16The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.00 to $99.9942 inclusive.
F17The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.8925 inclusive.
F18The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.00 to $101.98 inclusive.
F19The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.01 to $103.00 inclusive.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.95 to $90.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (4) and (7) through (19).
F20Fully vested and exercisable.
F3This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.03 inclusive.
F5These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
F6The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.04 inclusive.
F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.10 to $92.085 inclusive.
F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.1191 to $92.2833 inclusive.

Remarks

Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the first of two filings.